First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin Tissue
"We are dedicated to providing regenerative medicine advanced therapies to patients with serious complex skin wounds, such as burns and other trauma," said
About the Clinical Trial
The Phase 2 clinical study currently being investigated is titled "Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects." This range-finding study is designed to evaluate StrataGraft skin tissue as an alternative to autografting in promoting autologous tissue regeneration of the full-thickness component of complex skin defects resulting from acute traumatic skin loss (e.g., burn or degloving injuries). The study population will include patients with up to 49% total body surface area complex skin defects that include a full-thickness component.
Primary outcome measures will include the percent area of the StrataGraft treatment site requiring autografting by three months and wound closure of the treatment sites at three months. Targeted enrollment for this study is up to 20 patients with complex skin defects due to acute traumatic skin loss which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue. Study completion is expected by late 2018.
"We look forward to studying StrataGraft's potential to be a treatment option for patients with third-degree severe burns," said
Find more information about the trial here on the ClinicalTrials.gov website.
This work is supported by the
About Full-Thickness Burns
Full-thickness burns can also be referred to as third-degree burns. The standard of care for severe complex skin defects is the surgical harvesting of a sheet of healthy skin from an uninjured site on the patient and transplantation of this autologous skin graft to the injury once the wound is ready to receive an autograft. While this process can be effective in providing closure of the original wound, it has significant limitations related to the donor site wounds created during surgical removal of autologous skin tissue for grafting. These donor site wounds are extremely painful, prone to infection and scarring, and can themselves convert to full-thickness wounds that must then be managed to promote healing. In addition, the amount of healthy skin available for harvesting is frequently limited in large burns, necessitating sequential re-harvesting of available donor sites. As a result, there is an urgent need for alternatives to donor site harvesting for treatment of severe burns and other complex skin defects
About StrataGraft Regenerative Skin Tissue
StrataGraft regenerative skin tissue, is a viable, full-thickness product being developed for severe burns and other complex skin defects that is not yet approved by the
Senior Vice President, Investor Strategy and IRO
Director, Investor Relations
Senior Communications Manager
Chief Public Affairs Officer
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-patient-enrolled-in-mallinckrodt-phase-2-trial-of-stratagraft-regenerative-skin-tissue-300451527.html